Innova Captab Limited (NSE:INNOVACAP)

India · Delayed Price · Currency is INR

1,153.00

-14.40 (-1.23%)

Sep 11, 2026, 3:30 PM IST

Market Cap	65.65B +31.4%
Revenue (ttm)	17.49B +34.5%
Net Income	1.54B +18.7%
EPS	26.92 +18.7%
Shares Out	57.22M
PE Ratio	42.62
Forward PE	31.40
Dividend	3.00 (0.27%)
Ex-Dividend Date	Jan 30, 2026

Volume	44,086
Open	1,150.10
Previous Close	1,167.40
Day's Range	1,133.10 - 1,168.10
52-Week Range	622.00 - 1,200.00
Beta	-0.01
Analysts	Buy
Price Target	1,116.00 (-3.21%)
Earnings Date	Nov 6, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2005

Employees 1,600

Stock Exchange National Stock Exchange of India

Ticker Symbol INNOVACAP

Full Company Profile

Financial Performance

In fiscal year 2026, Innova Captab's revenue was 16.30 billion, an increase of 31.06% compared to the previous year's 12.44 billion. Earnings were 1.41 billion, an increase of 9.87%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for INNOVACAP stock is "Buy." The 12-month stock price target is ₹1,116, which is a decrease of -3.21% from the latest price.

Price Target

₹1,116

(-3.21% downside)

Analyst Consensus: Buy

Stock Forecasts